Exelixis Inc (EXEL) Stock Price, Trades & News

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Financial Strength

7/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	4.58
Equity-to-Asset	0.75
Debt-to-Equity	0.09
Debt-to-EBITDA	0.17
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	15.55	Distress Grey Safe
Beneish M-Score	-2.44	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	18.4
	3-Year EBITDA Growth Rate	68.4
	3-Year EPS without NRI Growth Rate	55.4
	3-Year FCF Growth Rate	63.1
	3-Year Book Growth Rate	2.3
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	18.04
	Future 3-5Y Total Revenue Growth Rate Estimate	11.76

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	61.67
	9-Day RSI	63.84
	14-Day RSI	63.55
	3-1 Month Momentum %	18.77
	6-1 Month Momentum %	19.39
	12-1 Month Momentum %	16.4

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.26
	Quick Ratio	3.19
	Cash Ratio	2.1
	Days Inventory	107.18
	Days Sales Outstanding	46.08
	Days Payable	127.71

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	6.8
	Shareholder Yield %	7.74

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	96.44
	Operating Margin %	40.29
	Net Margin %	35.08
	EBITDA Margin %	41.5
	FCF Margin %	38.1
	OCF Margin %	38.93
	ROE %	39.98
	ROA %	30.25
	ROIC %	46.17
	3-Year ROIIC %	1986.92
	ROC (Joel Greenblatt) %	228.7
	ROCE %	40.25
	Years of Profitability over Past 10-Year	9
	Moat Score	5
	Tariff Resilience Score	8

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	18.77
	Forward PE Ratio	17.71
	PE Ratio without NRI	16.92
	Shiller PE Ratio	43.8
	Price-to-Owner-Earnings	26.65
	PEG Ratio	0.36
	PS Ratio	6.58
	PB Ratio	7.4
	Price-to-Tangible-Book	7.66
	Price-to-Free-Cash-Flow	17.17
	Price-to-Operating-Cash-Flow	16.79
	EV-to-EBIT	14.2
	EV-to-Forward-EBIT	11.49
	EV-to-EBITDA	13.79
	EV-to-Forward-EBITDA	11.09
	EV-to-Revenue	5.72
	EV-to-Forward-Revenue	5.33
	EV-to-FCF	15.02
	Price-to-GF-Value	1.33
	Price-to-Projected-FCF	1.93
	Price-to-Median-PS-Value	1.13
	Price-to-Peter-Lynch-Fair-Value	0.68
	Price-to-Graham-Number	2.4
	Price-to-Net-Current-Asset-Value	26.04
	Price-to-Net-Cash	120.22
	Earnings Yield (Greenblatt) %	7.04
	FCF Yield %	6.37
	Forward Rate of Return (Yacktman) %	22.79

Financials (Next Earnings Date:2026-07-28 Est.)

Annual Quarterly TTM

EXEL's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with NAS:EXEL

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Exelixis Inc Executives

Details

GF Value™: $42.61

EXEL

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 5 Medium warning signs with EXEL. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	2,375.491
	EPS (TTM) ($)	3.01
	Beta	0.3059
	3-Year Sharpe Ratio	1.16
	3-Year Sortino Ratio	2.28
	Volatility %	32.39
	14-Day RSI	63.55
	14-Day ATR ($)	1.605252
	20-Day SMA ($)	54.02325
	12-1 Month Momentum %	16.4
	52-Week Range ($)	33.755 - 57.57
	Shares Outstanding (Mil)	251.36

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Exelixis Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Exelixis Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings conference call for 2026	2026-11-04 17:00	In 117 days
Third quarter earnings results for 2026	2026-11-04	In 116 days
Second quarter earnings conference call for 2026	2026-07-28 17:00	In 18 days
Second quarter earnings results for 2026	2026-07-28	In 17 days
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-09 10:40	51.74 (-1.91%)
Guidance call for 2026	2026-06-03 11:05	48.54 (-3.46%)
Bernstein 42nd Annual Strategic Decisions Conference	2026-05-27 15:30	49.98 (-1.13%)
General meeting for 2026	2026-05-26 09:00	50.15 (+0.80%)
Guidance call for 2026	2026-05-20 13:30	48.67 (-1.62%)
Guidance call for 2026	2026-05-19 09:00	49.84 (-0.95%)

Show

Entries

Exelixis Inc Frequently Asked Questions

What is Exelixis Inc(EXEL)'s stock price today?

The current price of EXEL is $56.51. The 52 week high of EXEL is $57.57 and 52 week low is $33.76.

When is next earnings date of Exelixis Inc(EXEL)?

The next earnings date of Exelixis Inc(EXEL) is 2026-07-28 Est..

Does Exelixis Inc(EXEL) pay dividends? If so, how much?

Exelixis Inc(EXEL) does not pay dividend.

Guru Commentaries on NAS:EXEL

No articles.

Press Release

	Subject	Date
	Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer	2026-06-22
	Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026	2026-05-30
	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June	2026-05-27
	Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types	2026-05-21
	Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer	2026-05-19
	Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026	2026-04-21
	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March	2026-02-24
	Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge	2026-02-24
	Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update	2026-02-10
	Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer	2026-02-02

10/Page

Articles on Exelixis Inc

EXEL

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

Jun 22, 2026

EXEL

Exelixis (EXEL) Reports Phase 3 Trial Results for Cancer Treatment

Jun 22, 2026

Headlines

Jun 22, 2026

Exelixis falls as final analysis of zanzalintinib phase 3 data disappoints

Seeking Alpha • 10:14am

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.